{"analyses":[{"ciLowerLimit":"0.39","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.73","groupDescription":"Physical Functioning: Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.53","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.84","groupDescription":"Role Functioning: Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0019","paramType":"Hazard Ratio (HR)","paramValue":"0.62","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","groupDescription":"GHS/QoL: Stratified by geographic region (Asia \\[excluding Japan\\] vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (\\<400 vs. \\>/= 400 ng/mL).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0028","paramType":"Hazard Ratio (HR)","paramValue":"0.63","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.48","upperLimit":"6.24","value":"4.86"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"9.69","upperLimit":"NA","value":"13.14"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.20","upperLimit":"5.98","value":"3.58"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"6.51","upperLimit":"NA","value":"9.13"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.02","upperLimit":"6.97","value":"3.58"},{"comment":"NA = not estimable due to the limited number of events observed","groupId":"OG001","lowerLimit":"5.98","upperLimit":"NA","value":"11.24"}]}],"title":"GHS/QoL"}],"denoms":[{"counts":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"336"}],"units":"Participants"}],"description":"TTD was defined as the time from randomization to the first deterioration (decrease from baseline of \\>/= 10 points) in the patient-reported health-related global health status/quality of life (GHS /HRQoL), physical function or role function scales of the European Organization for Research and Treatment of Cancer quality-of-life questionnaire for cancer (EORTC) QLQ-C30, maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in the Global population received sorafenib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG000","title":"Sorafenib - Global"},{"description":"Participants in the Global population received Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.","id":"OG001","title":"Atezolizumab + Bevacizumab - Global"}],"paramType":"MEDIAN","populationDescription":"Global ITT population consisted of all randomized participants in the Global population, whether or not the participant had received the assigned study treatment.","reportingStatus":"POSTED","timeFrame":"Randomization to the first occurrence of disease progression or death from any cause up to CCOD of 29Aug2019 (up to approximately 18 months)","title":"Time to Deterioration (TTD) in the Global Population","type":"SECONDARY","unitOfMeasure":"months"}